 |
|
Considering Competing Risks . . . Not All Black and White
Jane A. Cauley, DrPH;
Kristine E. Ensrud, MD, MPH
Arch Intern Med. 2008;168(8):793-795.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The world is not black and white. More like black and gray.
—Graham Greene
Osteoporosis and type 2 diabetes mellitus (DM), 2 of the most common chronic conditions, represent major public health burdens. The lifetime risk of an osteoporotic fracture ranges from 40% to 50% in women and from 13% to 22% in men.1-2 The goal of osteoporosis treatment is to reduce fractures because fractures cause significant morbidity and mortality. Diabetes mellitus affects 7% of the US population, or 20.8 million people.3 The goal of glucose-lowering treatment is to reduce long-term microvascular and macrovascular complications of the disease. Pharmacologic options for the treatment of osteoporosis and type 2 DM have expanded exponentially during the past decade.4-5 Trials in osteoporosis have demonstrated a reduction in risk of fracture with pharmacologic treatment. Trials in type 2 DM have demonstrated improvement in glycemic control . . . [Full Text of this Article] STRENGTH
CONSISTENCY
BIOLOGICAL PLAUSIBILITY
TEMPORALITY
SPECIFICITY
CONCLUSIONS
AUTHOR INFORMATION
RELATED ARTICLES
Use of Thiazolidinediones and Fracture Risk
Christian Meier, Marius E. Kraenzlin, Michael Bodmer, Susan S. Jick, Hershel Jick, and Christoph R. Meier
Arch Intern Med. 2008;168(8):820-825.
ABSTRACT
| FULL TEXT
Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
Susan R. Heckbert, Guo Li, Steven R. Cummings, Nicholas L. Smith, and Bruce M. Psaty
Arch Intern Med. 2008;168(8):826-831.
ABSTRACT
| FULL TEXT
|
